文献速递细菌感染、耐药与抗菌药物

即时多重分子诊断联合降钙素原指导算法用于下呼吸道感染抗菌药物管理的随机对照试验

Point-of-care multiplex molecular diagnosis coupled with procalcitonin-guided algorithm for antibiotic stewardship in lower respiratory tract infection: a randomized controlled trial.
PubMed 文献 · Clin Microbiol Infect · 2023-08-05

在急诊科开展开放标签前瞻性随机干预试验,2019至2022年纳入451例疑似下呼吸道感染患者,比较降钙素原(PCT)联合即时BIOFIRE RP2.1 plus检测及推荐抗菌药物算法与标准治疗。干预组与标准治疗组抗菌药物暴露中位时长分别为5天与6天(P=0.71),启动率分别为33.8%与29.6%(P=0.54),差异均未达统计学显著。

要点

  • 干预组与标准治疗组抗菌药物暴露中位时长分别为5天与6天(P=0.71)。
  • 干预组与标准治疗组抗菌药物启动率分别为33.8%(76/225)与29.6%(67/226)(P=0.54)。
  • 标准治疗组常规使用PCT测量,其中位抗菌药物时长和启动率已较低。

核心结论

  • 向急诊医生展示PCT和实时呼吸道病原体检测结果未能显著减少疑似下呼吸道感染患者的抗菌药物暴露。
  • 然而,常规使用PCT测量的标准治疗组中位抗菌药物时长和启动率已经较低。

研究设计与样本

  • 开放标签、前瞻性、随机干预试验,2019至2022年在成人急诊科开展。
  • 共随机451例疑似下呼吸道感染患者,中位年龄65岁(Q1-Q3:49-77),住院率59.9%(270/451),中位住院时长5天(Q1-Q3:3-12),28天死亡率5.3%(23/451)。
  • 干预组接受PCT测量和即时BIOFIRE RP2.1 plus检测,并附推荐抗菌药物算法;标准治疗组按当前实践允许使用PCT。

主要发现

  • 标准治疗组与干预组抗菌药物暴露中位时长分别为6天(Q1-Q3:0-9)与5天(Q1-Q3:0-9)(P=0.71)。
  • 标准治疗组与干预组抗菌药物启动率分别为29.6%(67/226)与33.8%(76/225)(P=0.54)。
  • 干预组中BIOFIRE RP2.1 plus在112/225例(49.8%)中鉴定出至少一种病毒物种。
  • 标准治疗组226例中212例(93.8%)进行了PCT测量。
  • 干预组对算法的依从率为93.3%(210/225)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to show that coupling molecular syndromic respiratory panel (RP) testing with procalcitonin (PCT) measurement in the emergency department improves antibiotic (ATB) stewardship in lower respiratory tract infection. METHODS: Open-label, prospective, randomized interventional trial, conducted from 2019 to 2022 in an adult emergency department. Patients with a suspicion of lower respiratory tract infection were randomized into an intervention arm (PCT measurement and point-of-care BIOFIRE RP2.1 plus testing, accompanied by a recommended ATB algorithm) or a standard of care (SOC) arm (PCT allowed as current practice). The primary endpoint was the duration of antibiotic exposure. RESULTS: Four hundred fifty-one patients were randomized, median age 65 years (Q1-Q3: 49-77), the hospitalization rate was 59.9% (270/451), the median length of stay 5 days (Q1-Q3: 3 - 12), and the 28-day mortality rate 5.3% (23/451). The median duration of ATB exposure was 6 days (Q1-Q3: 0-9) and 5 days (Q1-Q3: 0-9) in the SOC and interventional arm respectively (p = 0.71). ATB was started in 29.6 % (67/226) and 33.8% (76/225) respectively (p = 0.54). The BIOFIRE RP2.1 plus identified at least one viral species in 112/225 patients (49.8%) of intervention arm. Two hundred twelve out of two hundred twenty-six (93.8%) SOC patients had PCT measurement. The adherence rate to algorithm in the intervention arm was 93.3 % (210/225). CONCLUSION: Displaying PCT and real-time RP results to emergency physicians failed to significantly reduce ATB exposure in lower respiratory tract infection suspicions. However, the median ATB duration and rate of initiation were already low in the SOC arm using PCT measurement routinely.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Velly L, Cancella de Abreu M, Boutolleau D, et al. Point-of-care multiplex molecular diagnosis coupled with procalcitonin-guided algorithm for antibiotic stewardship in lower respiratory tract infection: a randomized controlled trial. Clin Microbiol Infect. 2023. PMID: 37549731. doi:10.1016/j.cmi.2023.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。